Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company
leveraging significant government funding to develop a platform of
novel compounds to protect against radiological and chemical
threats and for use in oncology, announced the appointment of John
M. Clerici, Mitchell D. Kaye, and Jeffrey A. Scott, M.D., to its
board of directors and accepted the resignations of Joseph J.
Krivulka, Michael E. Lewis, PhD, and Peter D. Suzdak, PhD.
"We are pleased to announce the addition of John, Mitch and
Jeffrey to the board of directors," stated David Cavalier, Chairman
of the board of directors. "John brings over 14 years of experience
in working with the US Government in public health preparedness,
and will contribute significantly to our medical countermeasure
development programs. Mitch's experience in business development
and financing biotech companies will be invaluable as we begin to
generate efficacy data from our animal efficacy and cancer studies.
Jeffrey's experience as an oncologist, drug developer and senior
executive in one of the leading pharmaceutical distribution
companies will be invaluable as we begin to move forward with our
AEOL 10150 oncology development program and begin to formulate our
strategies for making our compound available in the most efficient
and effective way for biodefense purposes. We also thank Joe
Krivulka, Michael Lewis and Peter Suzdak, for their dedication and
service to the board and shareholders of Aeolus over the past 8
years. Each of them made important contributions to Aeolus that
have helped position us for the next stage of our growth."
"Having the government contracting, business development and
oncology expertise that John, Mitch, and Jeffrey possess, will be
critical assets to the Company, as we transition from the
manufacturing and animal model development that characterized the
first two years of our BARDA contract, to animal efficacy, human
safety studies and ultimately procurement of AEOL 10150," stated
John L. McManus, President and Chief Executive Officer of Aeolus
Pharmaceuticals.
John M. Clerici is a founding Principal of Tiber Creek Partners,
LLC, a company focused on providing scientific and business
counseling to biotechnology companies seeking to use non-dilutive
capital from the U.S. and foreign governments and from
non-governmental organizations. Mr. Clerici is also a Partner in
the government contracts practice at McKenna Long & Aldridge
LLP. For over 14 years, Mr. Clerici has been at the forefront of
the creation of the public health preparedness sector, including
helping large pharmaceutical and emerging biotechnology companies
develop creative approaches to access non-dilutive capital to fund
the development of biotechnology for emerging disease and
engineered threats. Since 1999, Mr. Clerici has assisted over three
dozen companies in obtaining nearly $4 billion in funding for
research, development and procurement of public health
countermeasures from the Federal government, which includes the
majority of the awards made under Project Bioshield, the U.S.
Government's initiative for preparing the United States against a
bioterrorist attack. Prior to joining McKenna Long & Aldridge
LLP, Mr. Clerici was a judge advocate with the U.S. Air Force
where, among other assignments, he advised the Air Force Research
Laboratory on the procurement of technology from research
institutions throughout the United States, Europe and Asia. Mr.
Clerici earned his Juris Doctor from the University of North
Carolina at Chapel Hill in 1995. He did his undergraduate work at
the Catholic University of America, graduating summa cum laude.
Mitchell D. Kaye, J.D., is the Founder of MedClaims Liaison, LLC
and has served as its Chief Executive Officer since 2009. MedClaims
is a consumer advocacy business, which works on behalf of families
in managing reimbursement disputes with medical providers and
insurance companies. From 2008-2010, Mr. Kaye was a Managing
Director with Navigant Capital Advisors, a financial and strategic
advisory services firm, and Head of Navigant's Financial
Institutions Restructuring Solutions Team (FIRST). While at
Navigant, Mr. Kaye led numerous high profile engagements on behalf
of investment funds and investors. Previously, as a successful
entrepreneur in the asset management industry, Mr. Kaye launched
two highly profitable asset management companies. Mr. Kaye was the
founding member of Xmark Opportunity Partners, LLC, an investment
fund exclusively focused on investments in publicly traded life
sciences companies, and has served as a member of the management
committee since 2001. In 1996, Mr. Kaye began his career as a
founding member of Brown Simpson Asset Management, LLC (Brown
Simpson), an investment fund that was at the foreground of private
placement investing in the public markets. Brown Simpson's life
sciences investment unit produced a value weighted cash-on-cash
return in excess of 100% during the life of the fund. During his
career, Mr. Kaye has consummated over 100 transactions as a lead
investor, structured over a billion dollars in debt and
equity-linked transactions, and taken an active role in the
management of numerous portfolio companies. Mr. Kaye has served on
the boards of several private and public companies, and also served
on the board of the New York Alzheimer's Association. Mr. Kaye
received his BA from Wesleyan University, and his Juris Doctorate
from Northwestern University School of Law.
Jeffrey A. Scott, M.D., whose specialty is oncology, currently
is General Manager/Senior Vice President for P4 Healthcare, a
division of Cardinal Health Specialty Solutions, which is a
division of Cardinal Health. He is also a member of Cardinal
Health's Operating Committee. Prior to the 2010 sale of P4
Healthcare to Cardinal Health, Dr. Scott was the Founder, President
and Chief Executive Officer of P4 Healthcare, since its inception
in 2006. P4 Healthcare was a multimedia Healthcare Marketing and
Education Company with a focus in Oncology. From 1998 to 2002, Dr.
Scott served as the National Medical Director and President of the
International Oncology Network (ION), a network of more than 4,000
U.S. private practice oncologists headquartered in Baltimore,
Maryland. In 2002, ION became a subsidiary of Amerisource Bergen
Corporation upon its sale. Dr. Scott continued to serve as
President and General Manager for ION until 2005. Dr. Scott was a
practicing physician, Founding Partner and Chief Financial Officer
of Georgia Cancer Specialists located in Atlanta, Georgia from 1990
to 2000. During Dr. Scott's tenure as Chief Financial Officer of
Georgia Cancer Specialists, the physician practice had over $100
million in revenue and Dr. Scott was responsible for development of
financial programs of practice after the merger and corporate
buyout by Phymatrix. Also at the Georgia Cancer Specialists, Dr.
Scott took responsibility for the development of an extensive
clinical research program. From 1998 to 2000, he also served as
Medical Chief of Staff at Emory Northlake Regional Medical Center
in Atlanta, Georgia. Dr. Scott's biotechnology experience includes
his role as a Consultant to NexStar Pharmaceuticals, Inc. of
Boulder, Colorado. As a consultant to NexStar, Dr. Scott was
responsible for assisting and educating the sales force in dealing
with physician networks and consulting with investment advisors
regarding potential investments in other biotechnology companies.
Dr. Scott's educational background includes a B.S. degree in
Microbiology from the University of Michigan, Ann Arbor, Michigan,
a medical education at Wayne State University, Detroit, Michigan,
and a fellowship in Oncology at University of Texas Health
Sciences, San Antonio, Texas. Dr. Scott has Board Certifications
from the American Board of Internal Medicine, Internal Medicine,
September 1987, and the American Board of Internal Medicine,
Medical Oncology, November 1989. Dr. Scott has served on the board
of directors of Biovest International, Inc. since March 2004.
About AEOL 10150 AEOL 10150 is a
broad-spectrum catalytic antioxidant specifically designed to
neutralize reactive oxygen and nitrogen species. The neutralization
of these species reduces oxidative stress, inflammation, and
subsequent tissue damage-signaling cascades resulting from
radiation exposure. AEOL 10150 may have a profound beneficial
impact on people who have been exposed, or are about to be exposed,
to high-doses of radiation in the treatment of oncology.
AEOL 10150 has performed well in preclinical and non-clinical
studies, demonstrating statistically significant survival efficacy
in an acute radiation-induced lung injury model, and was
well-tolerated in two human clinical trials. The Company believes
it could have a profound beneficial impact on people who have been
exposed, or are about to be exposed, to high-doses of radiation,
whether from cancer therapy or a nuclear event.
About Aeolus Pharmaceuticals Aeolus
Pharmaceuticals is developing a platform of a new class of
broad-spectrum, catalytic-antioxidant compounds that protect
healthy tissue from the damaging effects of radiation. Its first
compound, AEOL 10150, is being developed for oncology indications,
where it is used in combination with radiation therapy. It is also
being developed, with funding by the US Department of Health and
Human Services, as a medical countermeasure against chemical and
radiological weapons, where its initial target indications are as a
protective agent against the effects of acute radiation syndrome
and delayed effects of acute radiation exposure. Aeolus' strategy
is to leverage the substantial investment in toxicology,
manufacturing, and preclinical and clinical studies made by US
Government agencies in AEOL 10150, including the contract with
BARDA valued, with options, at up to $118.4 million, to efficiently
develop the compound for use in oncology. For more information,
please visit Aeolus's corporate website at
www.aeoluspharma.com.
Forward-Looking Statements
The statements in this press release that are not purely
statements of historical fact are forward-looking statements. Such
statements include, but are not limited to, those relating to
Aeolus' product candidates, as well as its proprietary technologies
and research programs, the Company's potential initiation of large
efficacy studies in mice and NHPs, as well as a phase 1 study in
healthy normal volunteers, the BARDA Contract, and the expected use
of proceeds from the financing. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors
that may cause Aeolus' actual results to be materially different
from historical results or from any results expressed or implied by
such forward-looking statements. Important factors that could cause
results to differ include risks associated with uncertainties of
progress and timing of clinical trials, scientific research and
product development activities, difficulties or delays in
development, testing, obtaining regulatory approval, the need to
obtain funding for pre-clinical and clinical trials and operations,
the scope and validity of intellectual property protection for
Aeolus' product candidates, proprietary technologies and their
uses, and competition from other biopharmaceutical companies, and
whether BARDA exercises one or more additional options under the
BARDA Contract. Certain of these factors and others are more fully
described in Aeolus' filings with the Securities and Exchange
Commission, including, but not limited to, Aeolus' Annual Report on
Form 10-K for the year ended September 30, 2012. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Russell Skibsted Sr. Vice President and Chief Financial
Officer Aeolus Pharmaceuticals, Inc. 1-(949) 481-9825
Aeolus Pharmaceuticals (CE) (USOTC:AOLS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeolus Pharmaceuticals (CE) (USOTC:AOLS)
Historical Stock Chart
From Jul 2023 to Jul 2024